Co-Founder, Fate Therapeutics
Co-Founder and President, Institute for Systems Biology
Founding Partner, General Assembly
Co-Founder and Director of Mobile, Detroit Labs
Professor of Chemistry, Scripps Research Institute
Senior Managing Partner, Aisling Capital Fund
CEO and Managing Partner, Flagship Ventures
Partner, Voyager Capital
|
| Entry | Author | Date | Location | |
|---|---|---|---|---|
| Synta, Developer of New Class of Cancer Drugs, Eagerly Awaits Results From Key Trial | Luke Timmerman | 01/27/09 | Boston | |
| Synta Gets $25M From Glaxo For Cancer Drug Milestone | Luke Timmerman | 10/14/08 | Boston | |
| BioVex Viral Treatment Shrinks Melanoma Tumors in Trial | Luke Timmerman | 06/01/08 | Boston | |
| Page 2 of 2 | « previous page | |||
Business, life sciences, and technology news — covering Boston, Seattle, San Diego, Detroit, San Francisco, New York and beyond.
© 2007-2012, Xconomy, Inc. Xconomy is a registered service mark of Xconomy, Inc. All rights reserved.
Site produced by Andrew Koyfman with design from Rob Hunter.